$98.11 +0.22 (%) Celgene Corp - NASDAQ

Feb. 8, 2016 | 02:40 PM

Partner Headlines

  1. Barron's: Here Comes $20 Oil

    Benzinga | Feb. 7, 2016 | 11:12AM EST
  2. LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut

    IBD | Feb. 5, 2016 | 09:16AM EST
  3. Maybe Some Good News For A Big Biotech ETF

    Benzinga | Jan. 29, 2016 | 08:39AM EST
  4. Celgene Dips Lower Following Q4 Print

    Benzinga | Jan. 28, 2016 | 09:06AM EST
  5. Jim Cramer Dishes On Microsoft, Gilead, TG Therapeutics & NY Community Bancorp

    Benzinga | Jan. 24, 2016 | 19:56PM EST
  6. Big Earnings Expectations For Big Biotech

    Benzinga | Jan. 24, 2016 | 16:55PM EST
  7. Juno Buyout Puts Single-Cell Sequencing In Spotlight

    IBD | Jan. 15, 2016 | 17:30PM EST
  8. Stocks Reverse Higher To Big Gains; Intel Falls After Q4 Results

    IBD | Jan. 14, 2016 | 16:29PM EST
  9. Celgene Disappoints, Dips

    IBD | Jan. 11, 2016 | 19:29PM EST
  10. Celgene, Vertex, Illumina Offer Mixed Outlooks

    IBD | Jan. 11, 2016 | 19:05PM EST
  11. Stocks End Mixed; Alcoa Rises After Hours On Earnings

    IBD | Jan. 11, 2016 | 16:26PM EST
  12. Celgene Numbers Disappoint; New CEO Announced

    IBD | Jan. 11, 2016 | 13:59PM EST
  13. Stocks Turn Red As Biotechs, Energy Sink, But Macy's Rallies

    IBD | Jan. 11, 2016 | 13:44PM EST
  14. Baxalta Board Finally Accepts Shire's Takeover Offer

    IBD | Jan. 11, 2016 | 12:24PM EST
  15. Shares Of Celgene Plunge Following Busy Slate Of Announcements At JPMorgan Conference

    Benzinga | Jan. 11, 2016 | 12:02PM EST
  16. Celege 2016 Exp. Operational Milestones

    Benzinga | Jan. 11, 2016 | 11:13AM EST
  17. Benzinga's Top Initiations

    Benzinga | Jan. 7, 2016 | 09:37AM EST
  18. Jim Cramer Gives His Opinion On Lockheed Martin And Gilead Sciences

    Benzinga | Jan. 7, 2016 | 06:35AM EST
  19. DISH Network, H&R Block, Celgene, Plum Creek Timber Log Largest Insider Sells

    GuruFocus | Jan. 4, 2016 | 12:50PM EST
  20. Alphabet, Palo Alto Networks Lead Week's Insider Deals

    IBD | Dec. 31, 2015 | 13:59PM EST
  21. New IBD 50 Tech Stocks: LinkedIn Not The Only Network

    IBD | Dec. 28, 2015 | 19:13PM EST
  22. Celgene, Avago Lead IBD 50 Stocks For 'Santa Rally'

    IBD | Dec. 26, 2015 | 08:02AM EST
  23. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 24, 2015 | 08:19AM EST
  24. Benzinga's Volume Movers

    Benzinga | Dec. 23, 2015 | 10:28AM EST
  25. Stock Futures Catch Oil Updraft; Nike Rumbles, Micron Takes a Hit

    IBD | Dec. 23, 2015 | 09:02AM EST
  26. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 23, 2015 | 08:08AM EST
  27. Celgene Settles Patent Case

    IBD | Dec. 22, 2015 | 18:55PM EST
  28. After-Hours Action: Nike, Apple, Micron, Celgene

    IBD | Dec. 22, 2015 | 18:53PM EST
  29. After-Hours Movers Led By Nike, Micron, Celgene And CalAmp

    Benzinga | Dec. 22, 2015 | 17:13PM EST
  30. Celgene's Oral REVLIMID Plus Dexamethasone Given Approval to Treatment Patients with Newly Diagnosed Multiple Myeloma in Japan

    Benzinga | Dec. 21, 2015 | 04:23AM EST
  31. Gilead Buys Into Galapagos Drug That AbbVie Ditched

    IBD | Dec. 17, 2015 | 14:01PM EST
  32. Anemia-Drug Maker Plunges

    IBD | Dec. 7, 2015 | 18:52PM EST
  33. Taking a Look at Barron's 10 Favorite Stocks for 2016

    GuruFocus | Dec. 7, 2015 | 17:27PM EST
  34. Celgene, Acceleron Offer New Results from Study with Luspatercept in Beta-Thalassemia at ASH

    Benzinga | Dec. 7, 2015 | 17:01PM EST
  35. Bluebird Bio Craters After Gene Therapy Disappoints

    IBD | Dec. 7, 2015 | 14:32PM EST
  36. Celgene Announces IMiD Combination Therapies form Backbone of Multiple Myeloma Research at #ASH2015

    Benzinga | Dec. 6, 2015 | 08:41AM EST
  37. Celgene, Acceleron Announce New Results from Study with Luspatercept in Myelodysplastic Syndromes Presented at #ASH2015

    Benzinga | Dec. 5, 2015 | 13:03PM EST
  38. Celgene Announces Study of Bortezomib Added to Revlimid and Dexamethasone Backbone Therapy Presented at #ASH2015

    Benzinga | Dec. 5, 2015 | 11:35AM EST
  39. GoPro Downgraded, Ambarella PT Cut, Biotechs Are Buys

    IBD | Dec. 4, 2015 | 08:53AM EST
  40. Blood-Cancer Fighters To Strut Their Stuff At ASH

    IBD | Dec. 2, 2015 | 08:02AM EST
  41. Bristol-Myers Squibb's

    IBD | Nov. 30, 2015 | 18:49PM EST
  42. Biotechs Weaken, But These Names Have Bullish Charts

    IBD | Nov. 25, 2015 | 17:19PM EST
  43. Celgene: A Primer on Growth Stock Value Investing - Part 2

    GuruFocus | Nov. 13, 2015 | 15:46PM EST
  44. 3 Midsize Drug Stocks Moving On Q3 Reports

    IBD | Nov. 10, 2015 | 13:34PM EST
  45. Celgene's Mixed Bag In Q3

    IBD | Nov. 5, 2015 | 19:11PM EST
  46. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD | Nov. 5, 2015 | 17:37PM EST
  47. Stocks Slip; Disney Dips, Monster Roars After Hours

    IBD | Nov. 5, 2015 | 17:20PM EST
  48. Biotechs Sell Off Hard, But Indexes Cut Their Losses

    IBD | Nov. 5, 2015 | 16:22PM EST
  49. Facebook, Amazon Hit New Highs; Disney, Skyworks Report After Hours

    IBD | Nov. 5, 2015 | 14:51PM EST
  50. Celgene Reports Mixed Q3 As Cancer Rivals Rise

    IBD | Nov. 5, 2015 | 12:23PM EST
Trading Center